Novel Immune Targets in Melanoma-Letter

Affiliations

¹ Section of Pharmacology, Department of Medicine, University of Perugia, Perugia, Italy. giuseppe.nocentini@unipg.it.
² Section of Pharmacology, Department of Medicine, University of Perugia, Perugia, Italy.

Comment

Giuseppe Nocentini et al. Clin Cancer Res. 2019.

. 2019 Sep 1;25(17):5422-5423.

doi: 10.1158/1078-0432.CCR-19-1140.

¹ Section of Pharmacology, Department of Medicine, University of Perugia, Perugia, Italy. giuseppe.nocentini@unipg.it.
² Section of Pharmacology, Department of Medicine, University of Perugia, Perugia, Italy.

No abstract available

Comment in

Novel Immune Targets in Melanoma-Response.
Edwards J, Batten M, Ferguson A, Palendira U, Wilmott JS, Long GV, Scolyer RA. Edwards J, et al. Clin Cancer Res. 2019 Sep 1;25(17):5424-5425. doi: 10.1158/1078-0432.CCR-19-1866. Clin Cancer Res. 2019. PMID: 31481485 No abstract available.

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.
Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA. Edwards J, et al. Clin Cancer Res. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18. Clin Cancer Res. 2019. PMID: 30777877